$NKTR has been mentioned 14 times over the past 12 months by three distinct FinTwit voices, with the first mention appearing on September 18, 2025. Adam Feuerstein (@adamfeuerstein) dominates discussion with 12 mentions, while KawzInvests (@kawzinvests) and Shay Boloor (@stocksavvyshay) each contributed one mention. The most recent activity occurred on June 15, 2026.

Adam Feuerstein's coverage focused on clinical trial results, noting in April 2026 that $NKTR's rezpeg demonstrated a 27% clinically meaningful hair-growth response rate in alopecia areata at 52 weeks, comparing the outcome favorably to competitor Lilly's Olumiant. His subsequent mentions included $NKTR alongside other biotech stocks in portfolio references.